BRAIN CANCER

Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields, an antimitotic treatment.

Adding everolimus to chemoradiation did not have a significant treatment effect for patients with newly diagnosed glioblastoma, according to results from the phase II NRG Oncology RTOG 0913 trial.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.

Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer. 

Patients with oligodendroglioma developed pseudoprogression earlier after treatment with proton therapy compared with after photon therapy, according to the results of a retrospective study comparing the rates of pseudoprogression that occurred in patients with anaplastic gliomas following treatment with different radiation therapy modalities.

The combination of TTFields and temozolomide has been added by the NCCN to its guidelines for Category 1 treatment for patients with newly diagnosed glioblastoma, following maximal safe resection and completion of radiation therapy.

Prostate Cancer

Lung Cancer

David M. Ashley, MBBS, FRACP, PhD, has been named director of the Preston Robert Tisch Brain Tumor Center at Duke University. His position began March 1, 2018, and he succeeded Darell Bigner, MD, PhD.